foxo4 dri senolytic peptide human trial FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway FOXO4-DRI (FOX04-DRI) 10mg Peptide |

DSIP is a compounded prescription therapy not intended to treat, cure, or prevent any disease

Note: Luer lock plastic syringes are only for industrial, scientific laboratory, or household use

Sleep quality affects virtually every aspect of your health and wellness

GHK-Cu is specialized for collagen synthesis and skin regeneration, making it ideal for cosmetic and wound applications

Researchers tracking peptide clinical trial news should note these ongoing studies: NAFLD/NASH Research The most significant ongoing research involves tesamorelin NAFLD (nonalcoholic fatty liver disease) studies: Rationale: Tesamorelin's documented reduction of visceral adipose tissue may benefit hepatic fat accumulation Key studies: Multiple trials have evaluated tesamorelin's effects on liver fat content in HIV and non-HIV populations Published findings (2024-2025): Studies in JAMA Internal Medicine and Hepatology have documented reductions in hepatic fat fraction Latest tesamorelin research 2025-2026: Recent studies from 2024-2026 continue to evaluate hepatic fat reduction in non-HIV NAFLD/MASH populations, with new analyses examining long-term durability of VAT reduction Cognitive Function Studies Research has explored tesamorelin's effects on cognitive function, particularly in HIV patients where cognitive impairment is common: GH/IGF-1 axis involvement in neuroprotection Studies examining memory and executive function outcomes Ongoing investigation of mechanisms beyond metabolic effects Body Composition Research As a tesamorelin growth hormone analog, research continues into body composition effects: Trunk fat reduction Lipid profile improvements Metabolic marker changes ClinicalTrials.gov Listings Researchers can search ClinicalTrials.gov for "tesamorelin" to find current and completed studies